Antibody-Drug Conjugates: Oncology and Beyond

Antibody-Drug Conjugates: Oncology and Beyond

Tuesday, November 14, 2017, 9:00 AM - 5:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York, USA

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Antibody–Drug Conjugates (ADCs) combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise therapeutic approaches. This symposium will explore the opportunities and challenges of ADCs for cancer, and the need to resolve these open questions in order to fulfill the larger promise of this technology. We will also consider use of ADCs beyond cancer into other disease indications including autoimmune disease, difficult-to-treat bacterial infections, and atherosclerosis.

Call for Abstracts

Abstract submissions are invited for a poster session. For complete submission instructions, please visit our online portal. The deadline for abstract submission is  October 13, 2017.

Registration

Member
$60
Nonmember Academia, Faculty, etc.
$105
Nonmember Corporate, Other
$160
Nonmember Not for Profit
$105
Nonmember Student, Undergrad, Grad, Fellow
$70
Member Student, Post-Doc, Fellow
$25
Deadline:
0
days
left

Speakers

Antibody-Drug Conjugates: Oncology and Beyond
Philip E. Brandish, PhD, Merck & Co **
Antibody-Drug Conjugates: Oncology and Beyond
Ryan Fleming, PhD, MedImmune
Antibody-Drug Conjugates: Oncology and Beyond
Rakesh K. Jain, PhD, Harvard University **
Antibody-Drug Conjugates: Oncology and Beyond
Jessica R. Kirshner, PhD, Regeneron Pharmaceuticals **
Antibody-Drug Conjugates: Oncology and Beyond
Christopher J. O'Donnell, PhD, Pfizer
Antibody-Drug Conjugates: Oncology and Beyond
Laura Saunders, PhD, StemCentryx
Antibody-Drug Conjugates: Oncology and Beyond
Greg Thurber, PhD, University of Michigan
Antibody-Drug Conjugates: Oncology and Beyond
Man-Wah Tan, PhD, Genentech
Antibody-Drug Conjugates: Oncology and Beyond
Bob Stoffl, Abbvie

**will not be participating in the webinar

Sponsors

This event is proudly supported by:

Academy Friend

Mersana Therapeutics

The Biochemical Pharmacology Discussion Group is proudly supported by:

Regeneron


ACS New York Section

Premiere Supporter

Promotional Partners

New York Genome Center

American Society of Clinical Oncology (ASCO)

Tuesday

November 14, 2017

8:30 AM

Registration and Continental Breakfast

9:00 AM

Opening Remarks and Conference Overview

Speakers

Sonya Dougal, PhD
The New York Academy of Sciences
Pamela Trail, PhD
AGL Biotechnology

SESSION I: ANTIBODY DRUG CONJUGATES FOR ONCOLOGY

9:15 AM

Rovalpituzumab Tesirine, an anti-DLL3 ADC, for the Therapeutic Treatment of Tumors that Express DLL3

Speaker

Laura Saunders
StemCentryx
9:45 AM

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) ADC in PRLR-Positive Breast Cancers

Speaker

Jessica R. Kirshner **
Regeneron
10:15 AM

MEDI4276: Biparatopic ADC Targeting HER2 Positive Cancers

Speaker

Ryan Fleming
MedImmune
10:45 AM

Discovery of Novel Linker Payloads and Antibody Drug Conjugates for the Treatment of Cancer

Speaker

Christopher J. O’Donnell
Pfizer
11:15 AM

Networking Coffee Break

SESSION II: TUMOR MICROENVIRONMENT

11:45 AM

Reengineering the Tumor Microenvironment to Enhance Cancer Treatment: Bench to Bedside

Speaker

Rakesh Jain **
Harvard Medical School
12:15 PM

Tumoral Distribution of Antibody Drug Conjugates – Impact on Efficacy and Strategies

Speaker

Greg Thurber
University of Michigan
12:45 PM

Networking Lunch Break and Poster Session

SESSION III: OTHER INDICATIONS FOR ANTIBODY DRUG CONJUGATES

2:00 PM

TBD

Speaker

Man-Wah Tan
Genentech
2:30 PM

Targeting Glucocorticoids to Immune Cells as Antibody Drug Conjugates

Speaker

Philip E. Brandish **
Merck
3:00 PM

Anti-TNF- Glucocorticoid Antibody Drug Conjugate– A Disruptive Therapy for Rheumatic Diseases

Speaker

Robert Stoffel
Abbvie
3:30 PM

Networking Coffee Break

4:00 PM

Panel Discussion

Speaker

Gene Dubowchik (Moderator)
BioHaven Pharma
4:40 PM

F1000 Poster Prize Presentation and Closing Remarks

Speaker

Gene Dubowchik
BioHaven Pharma
4:45 PM

Networking Reception

5:45 PM

Adjourn